GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (LTS:0IIM) » Definitions » EV-to-Revenue

Esperion Therapeutics (LTS:0IIM) EV-to-Revenue : 1.97 (As of Jun. 03, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Esperion Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Esperion Therapeutics's enterprise value is $451.6 Mil. Esperion Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $229.7 Mil. Therefore, Esperion Therapeutics's EV-to-Revenue for today is 1.97.

The historical rank and industry rank for Esperion Therapeutics's EV-to-Revenue or its related term are showing as below:

LTS:0IIM' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.69   Med: 4.35   Max: 236.13
Current: 1.97

During the past 13 years, the highest EV-to-Revenue of Esperion Therapeutics was 236.13. The lowest was 1.69. And the median was 4.35.

LTS:0IIM's EV-to-Revenue is ranked better than
56.32% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs LTS:0IIM: 1.97

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-03), Esperion Therapeutics's stock price is $2.25. Esperion Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.55. Therefore, Esperion Therapeutics's PS Ratio for today is 1.45.


Esperion Therapeutics EV-to-Revenue Historical Data

The historical data trend for Esperion Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics EV-to-Revenue Chart

Esperion Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.71 2.44 3.89 7.40 4.62

Esperion Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.94 3.01 2.52 4.62 2.38

Competitive Comparison of Esperion Therapeutics's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Esperion Therapeutics's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's EV-to-Revenue falls into.



Esperion Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Esperion Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=451.613/229.74
=1.97

Esperion Therapeutics's current Enterprise Value is $451.6 Mil.
Esperion Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $229.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Esperion Therapeutics  (LTS:0IIM) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Esperion Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=2.25/1.553
=1.45

Esperion Therapeutics's share price for today is $2.25.
Esperion Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.55.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Esperion Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Esperion Therapeutics (LTS:0IIM) Business Description

Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.

Esperion Therapeutics (LTS:0IIM) Headlines

No Headlines